A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Speciality: Oncology

Description:

Welcome to this insightful panel discussion featuring renowned experts Dr. Srinivas K G, Dr. Abhaya Kumar S M, and Dr. Vishwanath S, as they delve into the critical topic of clinical trial endpoints for tumors with a Post-Progression Survival (PPS) exceeding 12 months. The panel explores the challenges and considerations in designing appropriate endpoints for long-surviving tumor patients, emphasizing the need for robust methodologies to accurately assess treatment efficacy. The experts share their perspectives on how extended PPS impacts trial design, patient outcomes, and regulatory decisions, offering valuable insights for oncologists and researchers.

The discussion further examines the implications of PPS > 12 months on overall survival (OS), progression-free survival (PFS), and other surrogate markers, highlighting the evolving landscape of cancer clinical trials. Dr. Srinivas, Dr. Abhaya, and Dr. Vishwanath provide evidence-based recommendations on optimizing endpoint selection to ensure meaningful data while addressing patient-centric outcomes. Their expertise sheds light on balancing statistical rigor with real-world clinical relevance, making this a must-watch for professionals in oncology research.

We hope this engaging conversation enhances your understanding of trial design in long-surviving tumor patients and inspires further exploration into innovative endpoint strategies. Stay tuned for more thought-provoking discussions from our esteemed panelists, as they continue to share their knowledge on advancing cancer research and improving patient care. Don’t forget to watch the full video and subscribe for future updates!

See More Webinars @ Hidoc Webinars